The mRNA-based RSV vaccine mRNA-1345 induces robust and durable CD4 + T cell responses against RSV in younger and older adults
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
We used intracellular cytokine staining, activation-induced marker, and Meso Scale Discovery assays and single-cell multiomic profiling to evaluate RSV vaccine mRNA-1345 responses in younger and older adults. mRNA-1345 induced comparable CD4 + and CD8 + T cell responses in both cohorts, with CD4 + responses persisting for 24 months.
Appeared: Friday, October 23. Science Advances. Peer-reviewed journal.